Singular Accounts Payable vs Total Current Assets Analysis
| OMIC Stock | USD 21.90 0.09 0.41% |
Singular Genomics financial indicator trend analysis is much more than just breaking down Singular Genomics Systems prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Singular Genomics Systems is a good investment. Please check the relationship between Singular Genomics Accounts Payable and its Total Current Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Accounts Payable vs Total Current Assets
Accounts Payable vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Singular Genomics Systems Accounts Payable account and Total Current Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Singular Genomics' Accounts Payable and Total Current Assets is 0.93. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Singular Genomics Systems, assuming nothing else is changed. The correlation between historical values of Singular Genomics' Accounts Payable and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Singular Genomics Systems are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Accounts Payable i.e., Singular Genomics' Accounts Payable and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.93 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Accounts Payable
An accounting item on the balance sheet that represents Singular Genomics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Singular Genomics Systems are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Singular Genomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Singular Genomics Systems current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. The current year's Enterprise Value is expected to grow to about 121.1 M, whereas Selling General Administrative is forecasted to decline to about 30.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.1M | 6.0M | 7.2M | 7.6M | Interest Income | 328K | 3.4M | 8.4M | 8.9M |
Singular Genomics fundamental ratios Correlations
Click cells to compare fundamentals
Singular Genomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Singular Genomics Systems offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Singular Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Singular Genomics Systems Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Singular Genomics Systems Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Singular Genomics Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share 1.107 | Quarterly Revenue Growth 0.459 | Return On Assets (0.24) | Return On Equity (0.52) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.